We've also heard about differential pricing that does not necessarily reflect production or transportation costs, but we still do not have adequate publicly available information on the prices companies are charging for their vaccines.
Mr. Gagnon, how important do you think it is to have access to data on not just the technology and manufacturing of the vaccines, but also the profits being made?
It is extremely hard to determine how much private companies are acting in the public interest and in a transparent manner, something governments should do as well. Information on how much money is being made on the vaccines stays confidential, so it's hard to know just how much companies are benefiting financially from the public funds they received and from intellectual property protections, to turn profits that go undisclosed, all during a global pandemic.